Amphion Innovations is a venture capital investment firm which specializes in seed, early-stage and later-stage investments. The firm prefers to invest in companies based in the United States and United Kingdom operating in the medical and technology sectors. It was incorporated in 1984 and is based in New York City.
Amphion Innovations does not invest in companies with technologies requiring long development timelines or excessive capital investment. They prefer investments in the medical, life sciences, and technology sectors with defensible core intellectual property, management experience and growth potential in markets of at least $1 billion in size together with corporations, governments, universities, and entrepreneurs.
The firm typically invests in companies with broad-based, proprietary, platform technologies in the areas of pharmacogenomics, proteomics, nutriceuticals or wellness, diagnostics, medical products and related fields, leveraging advances in and the convergence of materials science and life science IT, particularly software technologies. It targets investments in companies based in both the United States and United Kingdom.
Amphion Innovations makes investments in companies requiring capital of up to $5 million in the first one to two years, with additional capital requirements of between $15 million and $25 million and at least $1 billion in size. They act as a lead investor and seek to acquire a sizable ownership stake and measure of influence or control in their portfolio companies. The firm makes investments in the form of preferred stock or convertible debt or leverages through the ownership of stock warrants and stock options.
Raymond P. McKenzie
Richard C. E. Morgan
Robert J. Bertoldi
President and Chief Financial Officer